European CHMP recommends approval of biosimilar of trastuzumab (Zercepac)

Zercepac is intended for the treatment of early and metastatic breast cancer and metastatic gastric cancer. Data have shown that Zercepac has comparable quality, safety and efficacy to Herceptin (trastuzumab).

Source:

European Medicines Agency